Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ABEO NASDAQ:ALKS NASDAQ:MEDP NASDAQ:OMCL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABEOAbeona Therapeutics$5.49$5.09$4.00▼$7.54$312.88M1.351.13 million shs1.52 million shsALKSAlkermes$37.48$32.49$25.17▼$39.56$6.25B0.312.03 million shs1.32 million shsMEDPMedpace$415.27$463.68$287.17▼$628.92$11.86B1.19489,282 shs286,753 shsOMCLOmnicell$43.12$37.64$26.84▼$55.00$1.96B0.96695,569 shs549,733 shsThe 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABEOAbeona Therapeutics0.00%-6.95%-0.18%+9.58%-10.00%ALKSAlkermes0.00%+7.12%+8.54%+13.03%+19.29%MEDPMedpace0.00%-2.06%-20.23%-2.98%+35.86%OMCLOmnicell0.00%-1.60%+12.64%+18.14%+54.22%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABEOAbeona Therapeutics$5.49$5.09$4.00▼$7.54$312.88M1.351.13 million shs1.52 million shsALKSAlkermes$37.48$32.49$25.17▼$39.56$6.25B0.312.03 million shs1.32 million shsMEDPMedpace$415.27$463.68$287.17▼$628.92$11.86B1.19489,282 shs286,753 shsOMCLOmnicell$43.12$37.64$26.84▼$55.00$1.96B0.96695,569 shs549,733 shsThe 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABEOAbeona Therapeutics0.00%-6.95%-0.18%+9.58%-10.00%ALKSAlkermes0.00%+7.12%+8.54%+13.03%+19.29%MEDPMedpace0.00%-2.06%-20.23%-2.98%+35.86%OMCLOmnicell0.00%-1.60%+12.64%+18.14%+54.22%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABEOAbeona Therapeutics 2.33Hold$19.00246.08% UpsideALKSAlkermes 2.76Moderate Buy$45.4021.13% UpsideMEDPMedpace 2.20Hold$467.0812.48% UpsideOMCLOmnicell 3.00Buy$59.8638.82% UpsideCurrent Analyst Ratings BreakdownLatest ALKS, ABEO, MEDP, and OMCL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/13/2026ALKSAlkermes Robert W. BairdSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$45.00 ➝ $48.005/11/2026ALKSAlkermes Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C+) ➝ Hold (C)5/7/2026OMCLOmnicell Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (D) ➝ Hold (C-)5/6/2026ALKSAlkermes UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$42.00 ➝ $48.005/6/2026ALKSAlkermes Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$43.00 ➝ $44.005/6/2026ALKSAlkermes Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$45.00 ➝ $50.005/1/2026OMCLOmnicell Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Strong-Buy4/29/2026OMCLOmnicell Craig HallumSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$55.004/28/2026OMCLOmnicell KeyCorpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$60.00 ➝ $70.004/27/2026ALKSAlkermes Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold (C) ➝ Hold (C+)4/27/2026ALKSAlkermes Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold(Data available from 5/18/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABEOAbeona Therapeutics$5.82M53.76N/AN/A$2.94 per share1.87ALKSAlkermes$1.48B4.23$1.67 per share22.39$11.02 per share3.40MEDPMedpace$2.53B4.69$17.01 per share24.41$16.30 per share25.48OMCLOmnicell$1.18B1.66$2.77 per share15.59$27.45 per share1.57Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABEOAbeona Therapeutics$71.18M$0.975.6634.31N/AN/A-53.98%-38.52%N/AALKSAlkermes$241.66M$0.9041.6468.15N/A9.78%9.26%5.66%7/28/2026 (Estimated)MEDPMedpace$451.12M$15.9126.1022.402.1117.19%120.89%24.79%7/20/2026 (Estimated)OMCLOmnicell$2.05M$0.4498.0031.941.121.67%4.00%2.46%7/30/2026 (Estimated)Latest ALKS, ABEO, MEDP, and OMCL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2026Q1 2026ABEOAbeona Therapeutics-$0.33-$0.30+$0.03-$0.30$4.57 million$8.72 million4/28/2026Q1 2026OMCLOmnicell$0.33$0.55+$0.22$0.25$304.02 million$309.88 million4/22/2026Q1 2026MEDPMedpace$3.74$4.28+$0.54$4.28$697.82 million$706.60 million3/17/2026Q4 2025ABEOAbeona Therapeutics-$0.35-$0.34+$0.01-$0.34$5.65 million$3.00 million2/26/2026Q4 2025ALKSAlkermes$0.43$0.29-$0.14$0.29$380.44 million$384.55 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthABEOAbeona TherapeuticsN/AN/AN/AN/AN/AALKSAlkermesN/AN/AN/AN/AN/AMEDPMedpaceN/AN/AN/AN/AN/AOMCLOmnicellN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABEOAbeona Therapeutics0.035.895.70ALKSAlkermes0.852.271.70MEDPMedpaceN/A0.850.85OMCLOmnicell0.131.501.29Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABEOAbeona Therapeutics80.56%ALKSAlkermes95.21%MEDPMedpace77.98%OMCLOmnicell97.70%Insider OwnershipCompanyInsider OwnershipABEOAbeona Therapeutics5.40%ALKSAlkermes4.59%MEDPMedpace20.50%OMCLOmnicell2.92%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableABEOAbeona Therapeutics9056.99 million53.92 millionOptionableALKSAlkermes2,050166.68 million159.03 millionOptionableMEDPMedpace6,20028.56 million22.71 millionOptionableOMCLOmnicell3,58045.48 million44.15 millionOptionableALKS, ABEO, MEDP, and OMCL HeadlinesRecent News About These CompaniesDana Investment Advisors Inc. Purchases New Shares in Omnicell, Inc. $OMCL3 hours ago | marketbeat.comHere is What Analysts Are Saying About Omnicell, Inc. (OMCL)May 14, 2026 | insidermonkey.comHere is What Analysts Are Saying About Omnicell, Inc. (OMCL)May 14, 2026 | finance.yahoo.comWhat is Zacks Research's Estimate for Omnicell Q2 Earnings?May 14, 2026 | marketbeat.comOmnicell, Inc. (NASDAQ:OMCL) Given Consensus Recommendation of "Buy" by AnalystsMay 13, 2026 | americanbankingnews.comOmnicell, Inc. (OMCL) Presents at Bank of America Global Healthcare Conference 2026 TranscriptMay 12, 2026 | seekingalpha.comOmnicell (NASDAQ:OMCL) Raised to Strong-Buy at Wall Street ZenMay 10, 2026 | americanbankingnews.comOmnicell (NASDAQ:OMCL) Upgraded by Wall Street Zen to Strong-Buy RatingMay 10, 2026 | marketbeat.comVanguard Group Inc. Has $251.55 Million Holdings in Omnicell, Inc. $OMCLMay 9, 2026 | marketbeat.comIs It Time To Reassess Omnicell (OMCL) After Its 71% One Year Share Price ReboundMay 8, 2026 | finance.yahoo.comPier Capital LLC Grows Stock Holdings in Omnicell, Inc. $OMCLMay 8, 2026 | marketbeat.comHere's Why Omnicell (OMCL) is a Strong Momentum StockMay 7, 2026 | zacks.comOmnicell to Present at the BofA Securities 2026 Healthcare ConferenceMay 5, 2026 | timesargus.comTOmnicell (OMCL) is a Great Momentum Stock: Should You Buy?May 5, 2026 | zacks.com3 Medical Info Systems Stocks Riding the GenAI Wave in a Tough MarketMay 4, 2026 | zacks.comSurging Earnings Estimates Signal Upside for Omnicell (OMCL) StockMay 4, 2026 | zacks.comWall Street Analysts See a 41.19% Upside in Omnicell (OMCL): Can the Stock Really Move This High?May 4, 2026 | zacks.comAssessing Omnicell (OMCL) Valuation After Q1 Earnings Beat And Higher EPS GuidanceMay 3, 2026 | finance.yahoo.comOmnicell (NASDAQ:OMCL) Raised to Buy at Wall Street ZenMay 2, 2026 | marketbeat.comOmnicell Earnings Call Shows Profits Surging, Outlook RaisedMay 1, 2026 | theglobeandmail.comOmnicell Q1 Earnings & Revenues Top, Stock Up, Gross Margin RisesMay 1, 2026 | zacks.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesThe Real SpaceX Play: 5 Chip Stocks Powering the IPO Before It LaunchesBy Bridget Bennett | May 4, 20265 Stocks Positioned to Win the AI Data Center BuildoutBy Bridget Bennett | April 20, 2026Apple Talks Just Changed Everything for IntelBy Sam Quirke | May 6, 2026Here's Why the AI Infrastructure Story Is Just Getting Bigger for GOOGLBy Ryan Hasson | April 21, 2026As Broadcom Eclipses $2 Trillion, Private Credit Giants Wants InBy Leo Miller | May 17, 2026ALKS, ABEO, MEDP, and OMCL Company DescriptionsAbeona Therapeutics NASDAQ:ABEO$5.49 0.00 (0.00%) Closing price 05/15/2026 04:00 PM EasternExtended Trading$5.42 -0.07 (-1.20%) As of 07:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B. It is also developing ABO-201 gene therapy for juvenile Batten disease; ABO-202 gene therapy for treatment of infantile Batten disease; EB-201 for for epidermolysis bullosa (EB); ABO-301 for Fanconi anemia disorder; and ABO-302 using a novel CRISPR/Cas9-based gene editing approach to gene therapy program for rare blood diseases. Further, it is involved in marketing MuGard, a mucoadhesive oral wound rinse for the management of mucositis, stomatitis, aphthous ulcers, and traumatic ulcers. Abeona Therapeutics Inc. has collaborations with EB Research Partnership and Epidermolysis Bullosa Medical Research Foundation that focus on gene therapy treatments for EB; and Brammer Bio for commercial translation of ABO-102. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1989 and is based in Dallas, Texas.Alkermes NASDAQ:ALKS$37.48 0.00 (0.00%) Closing price 05/15/2026 04:00 PM EasternExtended Trading$37.28 -0.20 (-0.55%) As of 07:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.Medpace NASDAQ:MEDP$415.27 0.00 (0.00%) Closing price 05/15/2026 04:00 PM EasternExtended Trading$416.12 +0.85 (+0.20%) As of 04:27 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Medpace Holdings, Inc. engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance. The company was founded by August James Troendle in 1992 and is headquartered in Cincinnati, OH.Omnicell NASDAQ:OMCL$43.12 0.00 (0.00%) Closing price 05/15/2026 04:00 PM EasternExtended Trading$43.21 +0.09 (+0.21%) As of 07:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Omnicell, Inc., together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications. It also provides central pharmacy automation solutions; IV compounding robots; and inventory management software. In addition, the company provides single-dose automation solutions that fill and label a variety of patient-specific, single-dose medication blister packaging based on incoming prescriptions; fully automated and semi-automated filling equipment for institutional pharmacies to warrant automated packaging of medications; and medication blister card packaging and packaging supplies to enhance medication adherence in non-acute care settings. Further, it offers EnlivenHealth Patient Engagement, a web-based solutions. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. Omnicell, Inc. was incorporated in 1992 and is headquartered in Fort Worth, Texas. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Peloton Stock Gives Back Gains After Upbeat Earnings Report MarketBeat Week in Review – 05/11 - 05/15 Datavalut Gains Traction: 5 Reasons to Sell Now TMC Stock: Why This Pre-Revenue Miner Is Worth Watching Alphabet's Googlebook Brings Gemini AI to PC Hardware As Broadcom Eclipses $2 Trillion, Private Credit Giants Wants In Robinhood, SoFi, and Webull Are Telling Very Different Stories Viking Sails to All-Time Highs—Fundamentals Signal More to Come Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
